Wells Fargo Upgrades Editas Medicine to Overweight, Raises Price Target to $6

Benzinga Newsdesk www.benzinga.com Positive 85.3%

Neg 0% Neu 0% Pos 85.3%

Wells Fargo analyst Yanan Zhu upgrades Editas Medicine (NASDAQ:EDIT) from Equal-Weight to Overweight and raises the price target from $4 to $6.